O-GlcNAcylation: a pro-survival response to acute stress in the cardiovascular and central nervous systems
O-GlcNAcylation is a unique monosaccharide modification that is ubiquitously present [...]
O-GlcNAcylation and Its Roles in Neurodegenerative Diseases
As a non-classical post-translational modification, O-linked β-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) [...]
O-GlcNAcylation of TDP-43 Suppresses Proteinopathies and Promotes TDP-43’s mRNA Splicing Activity
Pathological TDP-43 aggregation is characteristic of several neurodegenerative diseases, including [...]
O-GlcNAcylation Ameliorates the Pathological Manifestations of Alzheimer’s Disease by Inhibiting Necroptosis
O-GlcNAcylation (O-linked β-N-acetylglucosaminylation) is notably decreased in Alzheimer's disease (AD) [...]
O-GlcNAcylation Regulates Dopamine Neuron Function, Survival and Degeneration in Parkinson Disease
The dopamine system in the midbrain is essential for volitional [...]
MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy
Deposition of hyperphosphorylated and aggregated tau protein in the central [...]
Mutant Huntingtin Disrupts the Nuclear Pore Complex
Huntington's disease (HD) is caused by an expanded CAG repeat [...]
The Discovery and Characterization of [18F]MK‐8553, a Novel PET Tracer for Imaging O‐GlcNAcase (OGA)
[18F]MK-8553 is a high affinity, selective OGA inhibitor with properties [...]
Alectos Therapeutics Announces FDA Orphan Drug Designation for MK-8719: An Investigational Small-molecule OGA Inhibitor for Treatment of Progressive Supranuclear Palsy
Advances Novel Tau-directed Strategy for Treating Neurodegenerative Disease Phase 1 [...]
Preclinical Data Disclosed for Tau PET Tracer MK-6240: A Potential Clinical Biomarker for OGA Inhibitor MK-8719
Apr 18, 2016 – Alectos Therapeutics partner Merck, known as MSD [...]